🇺🇸 TETA 4HCL (60-<W108) in United States

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FDA authorised TETA 4HCL (60-<W108) on 28 April 2022

Marketing authorisation

FDA — authorised 28 April 2022

Application: NDA215760
Marketing authorisation holder: ORPHALAN
Local brand name: CUVRIOR
Indication: TABLET — ORAL
Status: approved

Read official source →

Other Cardiovascular approved in United States

Frequently asked questions

Is TETA 4HCL (60-<W108) approved in United States?

Yes. FDA authorised it on 28 April 2022.

Who is the marketing authorisation holder for TETA 4HCL (60-<W108) in United States?

ORPHALAN holds the US marketing authorisation.